![Anti-MMAE (Monomethyl auristatin E) Antibodies and MMAE Conjugates: For PK/PD Studies on MMAE-ADC - Creative Diagnostics Anti-MMAE (Monomethyl auristatin E) Antibodies and MMAE Conjugates: For PK/PD Studies on MMAE-ADC - Creative Diagnostics](https://www.creative-diagnostics.com/upload/image/Anti-MMAE-Antibodies-and-Conjugates-For-PKPD-Studies-on-MMAE-ADC-1.png)
Anti-MMAE (Monomethyl auristatin E) Antibodies and MMAE Conjugates: For PK/PD Studies on MMAE-ADC - Creative Diagnostics
![Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice | Pharmaceutical Research Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice | Pharmaceutical Research](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs11095-021-03162-1/MediaObjects/11095_2021_3162_Fig3b_HTML.png)
Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice | Pharmaceutical Research
![Payload of Antibody-drug Conjugates (ADCs) — MMAE and MMAF Brief Introduction – Creative Biolabs ADC Blog Payload of Antibody-drug Conjugates (ADCs) — MMAE and MMAF Brief Introduction – Creative Biolabs ADC Blog](https://www.creative-biolabs.com/blog/adc/wp-content/uploads/2018/03/MMAE-and-MMAF.png)
Payload of Antibody-drug Conjugates (ADCs) — MMAE and MMAF Brief Introduction – Creative Biolabs ADC Blog
![A first-in-human antibody–drug conjugate: Hope for patients with advanced solid tumours? | Immunopaedia A first-in-human antibody–drug conjugate: Hope for patients with advanced solid tumours? | Immunopaedia](https://www.immunopaedia.org.za/wp-content/uploads/2019/04/020419.jpg)
A first-in-human antibody–drug conjugate: Hope for patients with advanced solid tumours? | Immunopaedia
![Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates](https://www.explorationpub.com/uploads/Article/A100264/100264-g001.jpg)
Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
![Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma - ScienceDirect Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0223523423004555-ga1.jpg)
Development of a MMAE-based antibody-drug conjugate targeting B7–H3 for glioblastoma - ScienceDirect
![Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. - Abstract - Europe PMC Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6927763/bin/kmab-12-01-1699768-g001.jpg)
Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies. - Abstract - Europe PMC
![Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer | Bioconjugate Chemistry Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer | Bioconjugate Chemistry](https://pubs.acs.org/cms/10.1021/acs.bioconjchem.2c00015/asset/images/large/bc2c00015_0002.jpeg)
Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer | Bioconjugate Chemistry
![Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy | Nature Communications Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-31601-z/MediaObjects/41467_2022_31601_Fig1_HTML.png)
Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy | Nature Communications
![Development of MMAE-trastuzumab ADCs. MC-VC-PAB-MMAE was conjugated to... | Download Scientific Diagram Development of MMAE-trastuzumab ADCs. MC-VC-PAB-MMAE was conjugated to... | Download Scientific Diagram](https://www.researchgate.net/publication/344139562/figure/fig1/AS:945197391310850@1602364027854/Development-of-MMAE-trastuzumab-ADCs-MC-VC-PAB-MMAE-was-conjugated-to-trastuzumab.png)
Development of MMAE-trastuzumab ADCs. MC-VC-PAB-MMAE was conjugated to... | Download Scientific Diagram
![Monomethyl auristatin E (MMAE, vedotin), la charge utile de cytotoxiques brentuximab vedotin anticorps conjugué Photo Stock - Alamy Monomethyl auristatin E (MMAE, vedotin), la charge utile de cytotoxiques brentuximab vedotin anticorps conjugué Photo Stock - Alamy](https://c8.alamy.com/compfr/dc825k/monomethyl-auristatin-e-mmae-vedotin-la-charge-utile-de-cytotoxiques-brentuximab-vedotin-anticorps-conjugue-dc825k.jpg)
Monomethyl auristatin E (MMAE, vedotin), la charge utile de cytotoxiques brentuximab vedotin anticorps conjugué Photo Stock - Alamy
![Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance | Nature Communications Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-021-23793-7/MediaObjects/41467_2021_23793_Fig1_HTML.png)